Related Experiment Video

Updated: May 22, 2026

Establishing 3D Endometrial Organoids from the Mouse Uterus
06:24

Establishing 3D Endometrial Organoids from the Mouse Uterus

Published on: January 6, 2023

Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility

Marta Annunziata1, Raul M Luque, Mario Durán-Prado

  • 1Laboratory of Molecular and Cellular Endocrinology, Department of Internal Medicine, University of Turin, Corso Dogliotti 14, 10126 Turin, Italy.

Human Reproduction (Oxford, England)
|May 17, 2012
PubMed
Abstract

Insights

The somatostatin/cortistatin (SST/CST) system is present in endometriosis. SST and its analogues inhibit the proliferation and migration of endometrial stromal cells, suggesting potential therapeutic applications for endometriosis treatment.

Area of Science:

  • Reproductive biology
  • Endocrinology
  • Molecular biology

Background:

  • Endometriosis involves ectopic endometrial cell implantation, characterized by increased proliferation and migration.
  • Somatostatin (SST) and Cortistatin (CST) are peptides that regulate cell growth and motility via SST receptors.
  • The SST/CST system's role in endometriosis requires further investigation.

Purpose of the Study:

  • To investigate the gene expression of the SST/CST system in endometriotic tissues and cells.
  • To determine the effect of SST and its analogues on platelet-derived growth factor (PDGF)-induced proliferation and motility in endometrial stromal cells (ESCs).

Main Methods:

  • Analysis of gene and protein expression of the SST/CST system in human endometriotic tissues, primary ESCs, and T HESCs.
  • Assessment of cell proliferation using the Alamar blue assay.
  • Evaluation of cell motility via wound healing assays and Western blotting for signaling pathway activation (ERK1/2, Akt).

Main Results:

  • SST, CST, and their receptors were expressed in endometriotic tissues, primary ESCs, and T HESCs.
  • SST, SOM230, octreotide, and CST inhibited PDGF-induced proliferation and migration in both cell types.
  • SST reduced vascular endothelial growth factor and metalloprotease-2 mRNA expression and inhibited ERK1/2 phosphorylation.

Conclusions:

  • The SST/CST system is expressed in endometriotic tissues and cells.
  • SST and its analogues demonstrate inhibitory effects on endometrial stromal cell proliferation and motility.
  • These findings suggest the SST/CST system as a potential therapeutic target for endometriosis.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Two Methods for Establishing Primary Human Endometrial Stromal Cells from Hysterectomy Specimens09:15

Two Methods for Establishing Primary Human Endometrial Stromal Cells from Hysterectomy Specimens

Published on: May 23, 2014

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...